Index - 2021

Ad26.COV2-S-vaccin AstraZenica 202129-34 CanSino 202129-34 ChAdOx1-S-vaccin 202129-34 Janssen 202129-34 Sputnik 202129-34 Vaxzevria® 202129-34 Vectorvaccins 202129-34 covid 202129-34 covid-19 202129-34 pandemie 202129-34 vaccin 202129-34 AIS CRPS 202147-56 Cervarix 202147-56 Gardasil 202147-56 HPV 202147-56 POTS 202147-56 baarmoederhalskanker 202147-56 bivalent 202147-56 cervixcarcinoom 202147-56 humaan papillomavirus 202147-56 nonavalent 202147-56 quadrivalent 202147-56 vaccinatie 202147-56 vermoeidheidssyndroom 202147-56 Aktiprol® amisulpride 202121-28 antipsychotica 202121-28 bijwerkingen 202121-28 meta-analyse 202121-28 netwerk meta-analyse 202121-28 amisulpride Aktiprol® 202121-28 antipsychotica 202121-28 bijwerkingen 202121-28 meta-analyse 202121-28 netwerk meta-analyse 202121-28 amputatie canagliflozine 202141-46 dapagliflozine 202141-46 diabetes mellitus type 2 202141-46 empagliflozine 202141-46 ertugliflozine 202141-46 gangreen van Fournier 202141-46 glucosespiegel 202141-46 hartfalen 202141-46 hba1c 202141-46 keto-acidose 202141-46 metformine 202141-46 secundaire preventie 202141-46 sglt-2-remmers 202141-46 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46 angina CVA 20211-4 LDL-cholesterol 20211-4 TIA 20211-4 beroerte 20211-4 cardiovasculair 20211-4 cerebrovasculair 20211-4 ezetimib 20211-4 hersenbloeding 20211-4 herseninfarct 20211-4 myocardinfarct 20211-4 revascularisatie 20211-4 richtlijnen 20211-4 statinen 20211-4 streefwaarden 20211-4 antipsychotica Aktiprol® 202121-28 amisulpride 202121-28 bijwerkingen 202121-28 meta-analyse 202121-28 netwerk meta-analyse 202121-28 aritmie atrium flutter 202117-20 atriumfibrilleren 202117-20 hartritmestoornis 202117-20 medisch hulpmiddel 202117-20 medische app 202117-20 screening 202117-20 AstraZenica Ad26.COV2-S-vaccin 202129-34 CanSino 202129-34 ChAdOx1-S-vaccin 202129-34 Janssen 202129-34 Sputnik 202129-34 Vaxzevria® 202129-34 Vectorvaccins 202129-34 covid 202129-34 covid-19 202129-34 pandemie 202129-34 vaccin 202129-34 atrium flutter aritmie 202117-20 atriumfibrilleren 202117-20 hartritmestoornis 202117-20 medisch hulpmiddel 202117-20 medische app 202117-20 screening 202117-20 atriumfibrilleren aritmie 202117-20 atrium flutter 202117-20 hartritmestoornis 202117-20 medisch hulpmiddel 202117-20 medische app 202117-20 screening 202117-20 baarmoederhalskanker AIS 202147-56 CRPS 202147-56 Cervarix 202147-56 Gardasil 202147-56 HPV 202147-56 POTS 202147-56 bivalent 202147-56 cervixcarcinoom 202147-56 humaan papillomavirus 202147-56 nonavalent 202147-56 quadrivalent 202147-56 vaccinatie 202147-56 vermoeidheidssyndroom 202147-56 bamlanivimab SARS-CoV-2 2021 casirivimab 2021 covid-19 2021 covidpandemie 2021 covidpatiënten 2021 etesevimab 2021 imdevimab 2021 immuungecompromitteerden 2021 longcovid 2021 monoklonale antilichamen 2021 neutraliserende monoklonale antilichamen 2021 pandemie 2021 regdanvimab 2021 sotrovimab 2021 beroerte CVA 20211-4 LDL-cholesterol 20211-4 TIA 20211-4 angina 20211-4 cardiovasculair 20211-4 cerebrovasculair 20211-4 ezetimib 20211-4 hersenbloeding 20211-4 herseninfarct 20211-4 myocardinfarct 20211-4 revascularisatie 20211-4 richtlijnen 20211-4 statinen 20211-4 streefwaarden 20211-4 beschermingsduur COVID-19 202113-16 Comirnaty 202113-16 Moderna 202113-16 SARS-CoV-2 202113-16 doelgroep 202113-16 mRNA 202113-16 messenger-RNA 202113-16 pandemie 202113-16 tozinameran 202113-16 uitwisselbaarheid 202113-16 vaccin 202113-16 virusmutatie 202113-16 bijwerkingen Aktiprol® 202121-28 EMA 202157-62 FDA 202157-62 amisulpride 202121-28 antipsychotica 202121-28 bloedglucoseverlagende middel 202157-62 diabetes 202157-62 epidemiologisch onderzoek 20215-7 gerandomiseerd onderzoek 202157-62 meta-analyse 202121-28 myocardinfarct 202157-62 netwerk meta-analyse 202121-28 observationeel onderzoek 202157-62 post-marketing surveillance 20215-7 registratie 202157-62 registratieonderzoek 20215-7 richtlijnen 202157-62 rosiglitazon 202157-62 vaccins 20215-7 vaccinvigilantie 20215-7 bivalent AIS 202147-56 CRPS 202147-56 Cervarix 202147-56 Gardasil 202147-56 HPV 202147-56 POTS 202147-56 baarmoederhalskanker 202147-56 cervixcarcinoom 202147-56 humaan papillomavirus 202147-56 nonavalent 202147-56 quadrivalent 202147-56 vaccinatie 202147-56 vermoeidheidssyndroom 202147-56 bloedglucoseverlagende middel EMA 202157-62 FDA 202157-62 bijwerkingen 202157-62 diabetes 202157-62 gerandomiseerd onderzoek 202157-62 myocardinfarct 202157-62 observationeel onderzoek 202157-62 registratie 202157-62 richtlijnen 202157-62 rosiglitazon 202157-62 canagliflozine amputatie 202141-46 dapagliflozine 202141-46 diabetes mellitus type 2 202141-46 empagliflozine 202141-46 ertugliflozine 202141-46 gangreen van Fournier 202141-46 glucosespiegel 202141-46 hartfalen 202141-46 hba1c 202141-46 keto-acidose 202141-46 metformine 202141-46 secundaire preventie 202141-46 sglt-2-remmers 202141-46 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46 canakinumab MACE 2021 cardiovasculaire mortaliteit 2021 colchicine 2021 coronaire hartziekten 2021 in-stent-restenose 2021 myocardinfarct 2021 secundaire preventie 2021 stents 2021 CanSino Ad26.COV2-S-vaccin 202129-34 AstraZenica 202129-34 ChAdOx1-S-vaccin 202129-34 Janssen 202129-34 Sputnik 202129-34 Vaxzevria® 202129-34 Vectorvaccins 202129-34 covid 202129-34 covid-19 202129-34 pandemie 202129-34 vaccin 202129-34 cardiovasculair CVA 20211-4 LDL-cholesterol 20211-4 TIA 20211-4 angina 20211-4 beroerte 20211-4 cerebrovasculair 20211-4 ezetimib 20211-4 hersenbloeding 20211-4 herseninfarct 20211-4 myocardinfarct 20211-4 revascularisatie 20211-4 richtlijnen 20211-4 statinen 20211-4 streefwaarden 20211-4 cardiovasculaire mortaliteit MACE 2021 canakinumab 2021 colchicine 2021 coronaire hartziekten 2021 in-stent-restenose 2021 myocardinfarct 2021 secundaire preventie 2021 stents 2021 casirivimab SARS-CoV-2 2021 bamlanivimab 2021 covid-19 2021 covidpandemie 2021 covidpatiënten 2021 etesevimab 2021 imdevimab 2021 immuungecompromitteerden 2021 longcovid 2021 monoklonale antilichamen 2021 neutraliserende monoklonale antilichamen 2021 pandemie 2021 regdanvimab 2021 sotrovimab 2021 cerebrovasculair CVA 20211-4 LDL-cholesterol 20211-4 TIA 20211-4 angina 20211-4 beroerte 20211-4 cardiovasculair 20211-4 ezetimib 20211-4 hersenbloeding 20211-4 herseninfarct 20211-4 myocardinfarct 20211-4 revascularisatie 20211-4 richtlijnen 20211-4 statinen 20211-4 streefwaarden 20211-4 Cervarix AIS 202147-56 CRPS 202147-56 Gardasil 202147-56 HPV 202147-56 POTS 202147-56 baarmoederhalskanker 202147-56 bivalent 202147-56 cervixcarcinoom 202147-56 humaan papillomavirus 202147-56 nonavalent 202147-56 quadrivalent 202147-56 vaccinatie 202147-56 vermoeidheidssyndroom 202147-56 cervixcarcinoom AIS 202147-56 CRPS 202147-56 Cervarix 202147-56 Gardasil 202147-56 HPV 202147-56 POTS 202147-56 baarmoederhalskanker 202147-56 bivalent 202147-56 humaan papillomavirus 202147-56 nonavalent 202147-56 quadrivalent 202147-56 vaccinatie 202147-56 vermoeidheidssyndroom 202147-56 ChAdOx1-S-vaccin Ad26.COV2-S-vaccin 202129-34 AstraZenica 202129-34 CanSino 202129-34 Janssen 202129-34 Sputnik 202129-34 Vaxzevria® 202129-34 Vectorvaccins 202129-34 covid 202129-34 covid-19 202129-34 pandemie 202129-34 vaccin 202129-34 clopidogrel CYP2C19 20219-12 P2Y12-remmers 20219-12 PCI 20219-12 cytochroom P450 20219-12 genotypering 20219-12 intermediate metabolizer 20219-12 leverenzymen 20219-12 percutane coronaire interventie 20219-12 poor metabolizer 20219-12 prasugrel 20219-12 stentplaatsing 20219-12 stents 20219-12 ticagrelor 20219-12 tromboseprofylaxe 20219-12 colchicine MACE 2021 canakinumab 2021 cardiovasculaire mortaliteit 2021 coronaire hartziekten 2021 in-stent-restenose 2021 myocardinfarct 2021 secundaire preventie 2021 stents 2021 Comirnaty COVID-19 202113-16 Moderna 202113-16 SARS-CoV-2 202113-16 beschermingsduur 202113-16 doelgroep 202113-16 mRNA 202113-16 messenger-RNA 202113-16 pandemie 202113-16 tozinameran 202113-16 uitwisselbaarheid 202113-16 vaccin 202113-16 virusmutatie 202113-16 coronaire hartziekten MACE 2021 canakinumab 2021 cardiovasculaire mortaliteit 2021 colchicine 2021 in-stent-restenose 2021 myocardinfarct 2021 secundaire preventie 2021 stents 2021 corticosteroïden COVID-19 202163-68 SARS-CoV-2 202163-68 covidpneumonie 202163-68 dexamethason 202163-68 interleukine-6-antagonist 202163-68 pandemie 202163-68 sarilumab 202163-68 tocilizumab 202163-68 zuurstoftherapie 202163-68 covid Ad26.COV2-S-vaccin 202129-34 AstraZenica 202129-34 CanSino 202129-34 ChAdOx1-S-vaccin 202129-34 Janssen 202129-34 Sputnik 202129-34 Vaxzevria® 202129-34 Vectorvaccins 202129-34 covid-19 202129-34 pandemie 202129-34 vaccin 202129-34 COVID-19 Comirnaty 202113-16 Moderna 202113-16 SARS-CoV-2 202113-16 SARS-CoV-2 202163-68 beschermingsduur 202113-16 corticosteroïden 202163-68 covidpneumonie 202163-68 dexamethason 202163-68 doelgroep 202113-16 interleukine-6-antagonist 202163-68 mRNA 202113-16 messenger-RNA 202113-16 pandemie 202113-16 pandemie 202163-68 sarilumab 202163-68 tocilizumab 202163-68 tozinameran 202113-16 uitwisselbaarheid 202113-16 vaccin 202113-16 virusmutatie 202113-16 zuurstoftherapie 202163-68 covid-19 Ad26.COV2-S-vaccin 202129-34 AstraZenica 202129-34 CanSino 202129-34 ChAdOx1-S-vaccin 202129-34 Janssen 202129-34 SARS-CoV-2 2021 Sputnik 202129-34 Vaxzevria® 202129-34 Vectorvaccins 202129-34 bamlanivimab 2021 casirivimab 2021 covid 202129-34 covidpandemie 2021 covidpatiënten 2021 etesevimab 2021 imdevimab 2021 immuungecompromitteerden 2021 longcovid 2021 monoklonale antilichamen 2021 neutraliserende monoklonale antilichamen 2021 pandemie 202129-34 pandemie 2021 regdanvimab 2021 sotrovimab 2021 vaccin 202129-34 covidpandemie SARS-CoV-2 2021 bamlanivimab 2021 casirivimab 2021 covid-19 2021 covidpatiënten 2021 etesevimab 2021 imdevimab 2021 immuungecompromitteerden 2021 longcovid 2021 monoklonale antilichamen 2021 neutraliserende monoklonale antilichamen 2021 pandemie 2021 regdanvimab 2021 sotrovimab 2021 covidpatiënten SARS-CoV-2 2021 bamlanivimab 2021 casirivimab 2021 covid-19 2021 covidpandemie 2021 etesevimab 2021 imdevimab 2021 immuungecompromitteerden 2021 longcovid 2021 monoklonale antilichamen 2021 neutraliserende monoklonale antilichamen 2021 pandemie 2021 regdanvimab 2021 sotrovimab 2021 covidpneumonie COVID-19 202163-68 SARS-CoV-2 202163-68 corticosteroïden 202163-68 dexamethason 202163-68 interleukine-6-antagonist 202163-68 pandemie 202163-68 sarilumab 202163-68 tocilizumab 202163-68 zuurstoftherapie 202163-68 CRPS AIS 202147-56 Cervarix 202147-56 Gardasil 202147-56 HPV 202147-56 POTS 202147-56 baarmoederhalskanker 202147-56 bivalent 202147-56 cervixcarcinoom 202147-56 humaan papillomavirus 202147-56 nonavalent 202147-56 quadrivalent 202147-56 vaccinatie 202147-56 vermoeidheidssyndroom 202147-56 CVA LDL-cholesterol 20211-4 TIA 20211-4 angina 20211-4 beroerte 20211-4 cardiovasculair 20211-4 cerebrovasculair 20211-4 ezetimib 20211-4 hersenbloeding 20211-4 herseninfarct 20211-4 myocardinfarct 20211-4 revascularisatie 20211-4 richtlijnen 20211-4 statinen 20211-4 streefwaarden 20211-4 CYP2C19 P2Y12-remmers 20219-12 PCI 20219-12 clopidogrel 20219-12 cytochroom P450 20219-12 genotypering 20219-12 intermediate metabolizer 20219-12 leverenzymen 20219-12 percutane coronaire interventie 20219-12 poor metabolizer 20219-12 prasugrel 20219-12 stentplaatsing 20219-12 stents 20219-12 ticagrelor 20219-12 tromboseprofylaxe 20219-12 cytochroom P450 CYP2C19 20219-12 P2Y12-remmers 20219-12 PCI 20219-12 clopidogrel 20219-12 genotypering 20219-12 intermediate metabolizer 20219-12 leverenzymen 20219-12 percutane coronaire interventie 20219-12 poor metabolizer 20219-12 prasugrel 20219-12 stentplaatsing 20219-12 stents 20219-12 ticagrelor 20219-12 tromboseprofylaxe 20219-12 dapagliflozine amputatie 202141-46 canagliflozine 202141-46 diabetes mellitus type 2 202141-46 empagliflozine 202141-46 ertugliflozine 202141-46 gangreen van Fournier 202141-46 glucosespiegel 202141-46 hartfalen 202141-46 hba1c 202141-46 keto-acidose 202141-46 metformine 202141-46 secundaire preventie 202141-46 sglt-2-remmers 202141-46 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46 dexamethason COVID-19 202163-68 SARS-CoV-2 202163-68 corticosteroïden 202163-68 covidpneumonie 202163-68 interleukine-6-antagonist 202163-68 pandemie 202163-68 sarilumab 202163-68 tocilizumab 202163-68 zuurstoftherapie 202163-68 diabetes EMA 202157-62 FDA 202157-62 bijwerkingen 202157-62 bloedglucoseverlagende middel 202157-62 gerandomiseerd onderzoek 202157-62 myocardinfarct 202157-62 observationeel onderzoek 202157-62 registratie 202157-62 richtlijnen 202157-62 rosiglitazon 202157-62 diabetes mellitus type 2 amputatie 202141-46 canagliflozine 202141-46 dapagliflozine 202141-46 empagliflozine 202141-46 ertugliflozine 202141-46 gangreen van Fournier 202141-46 glucosespiegel 202141-46 hartfalen 202141-46 hba1c 202141-46 keto-acidose 202141-46 metformine 202141-46 secundaire preventie 202141-46 sglt-2-remmers 202141-46 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46 doelgroep COVID-19 202113-16 Comirnaty 202113-16 Moderna 202113-16 SARS-CoV-2 202113-16 beschermingsduur 202113-16 mRNA 202113-16 messenger-RNA 202113-16 pandemie 202113-16 tozinameran 202113-16 uitwisselbaarheid 202113-16 vaccin 202113-16 virusmutatie 202113-16 EGFR-tyrokinaseremmer Erlotinib 202135-40 NSCLC 202135-40 Tarceva® 202135-40 epidermale groeifactorreceptor 202135-40 extramurale behandeling 202135-40 niet-kleincellig longcarcinoom 202135-40 overleving 202135-40 progressievrij 202135-40 EMA FDA 202157-62 bijwerkingen 202157-62 bloedglucoseverlagende middel 202157-62 diabetes 202157-62 gerandomiseerd onderzoek 202157-62 myocardinfarct 202157-62 observationeel onderzoek 202157-62 registratie 202157-62 richtlijnen 202157-62 rosiglitazon 202157-62 empagliflozine amputatie 202141-46 canagliflozine 202141-46 dapagliflozine 202141-46 diabetes mellitus type 2 202141-46 ertugliflozine 202141-46 gangreen van Fournier 202141-46 glucosespiegel 202141-46 hartfalen 202141-46 hba1c 202141-46 keto-acidose 202141-46 metformine 202141-46 secundaire preventie 202141-46 sglt-2-remmers 202141-46 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46 epidemiologisch onderzoek bijwerkingen 20215-7 post-marketing surveillance 20215-7 registratieonderzoek 20215-7 vaccins 20215-7 vaccinvigilantie 20215-7 epidermale groeifactorreceptor EGFR-tyrokinaseremmer 202135-40 Erlotinib 202135-40 NSCLC 202135-40 Tarceva® 202135-40 extramurale behandeling 202135-40 niet-kleincellig longcarcinoom 202135-40 overleving 202135-40 progressievrij 202135-40 Erlotinib EGFR-tyrokinaseremmer 202135-40 NSCLC 202135-40 Tarceva® 202135-40 epidermale groeifactorreceptor 202135-40 extramurale behandeling 202135-40 niet-kleincellig longcarcinoom 202135-40 overleving 202135-40 progressievrij 202135-40 ertugliflozine amputatie 202141-46 canagliflozine 202141-46 dapagliflozine 202141-46 diabetes mellitus type 2 202141-46 empagliflozine 202141-46 gangreen van Fournier 202141-46 glucosespiegel 202141-46 hartfalen 202141-46 hba1c 202141-46 keto-acidose 202141-46 metformine 202141-46 secundaire preventie 202141-46 sglt-2-remmers 202141-46 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46 etesevimab SARS-CoV-2 2021 bamlanivimab 2021 casirivimab 2021 covid-19 2021 covidpandemie 2021 covidpatiënten 2021 imdevimab 2021 immuungecompromitteerden 2021 longcovid 2021 monoklonale antilichamen 2021 neutraliserende monoklonale antilichamen 2021 pandemie 2021 regdanvimab 2021 sotrovimab 2021 extramurale behandeling EGFR-tyrokinaseremmer 202135-40 Erlotinib 202135-40 NSCLC 202135-40 Tarceva® 202135-40 epidermale groeifactorreceptor 202135-40 niet-kleincellig longcarcinoom 202135-40 overleving 202135-40 progressievrij 202135-40 ezetimib CVA 20211-4 LDL-cholesterol 20211-4 TIA 20211-4 angina 20211-4 beroerte 20211-4 cardiovasculair 20211-4 cerebrovasculair 20211-4 hersenbloeding 20211-4 herseninfarct 20211-4 myocardinfarct 20211-4 revascularisatie 20211-4 richtlijnen 20211-4 statinen 20211-4 streefwaarden 20211-4 FDA EMA 202157-62 bijwerkingen 202157-62 bloedglucoseverlagende middel 202157-62 diabetes 202157-62 gerandomiseerd onderzoek 202157-62 myocardinfarct 202157-62 observationeel onderzoek 202157-62 registratie 202157-62 richtlijnen 202157-62 rosiglitazon 202157-62 gangreen van Fournier amputatie 202141-46 canagliflozine 202141-46 dapagliflozine 202141-46 diabetes mellitus type 2 202141-46 empagliflozine 202141-46 ertugliflozine 202141-46 glucosespiegel 202141-46 hartfalen 202141-46 hba1c 202141-46 keto-acidose 202141-46 metformine 202141-46 secundaire preventie 202141-46 sglt-2-remmers 202141-46 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46 Gardasil AIS 202147-56 CRPS 202147-56 Cervarix 202147-56 HPV 202147-56 POTS 202147-56 baarmoederhalskanker 202147-56 bivalent 202147-56 cervixcarcinoom 202147-56 humaan papillomavirus 202147-56 nonavalent 202147-56 quadrivalent 202147-56 vaccinatie 202147-56 vermoeidheidssyndroom 202147-56 genotypering CYP2C19 20219-12 P2Y12-remmers 20219-12 PCI 20219-12 clopidogrel 20219-12 cytochroom P450 20219-12 intermediate metabolizer 20219-12 leverenzymen 20219-12 percutane coronaire interventie 20219-12 poor metabolizer 20219-12 prasugrel 20219-12 stentplaatsing 20219-12 stents 20219-12 ticagrelor 20219-12 tromboseprofylaxe 20219-12 gerandomiseerd onderzoek EMA 202157-62 FDA 202157-62 bijwerkingen 202157-62 bloedglucoseverlagende middel 202157-62 diabetes 202157-62 myocardinfarct 202157-62 observationeel onderzoek 202157-62 registratie 202157-62 richtlijnen 202157-62 rosiglitazon 202157-62 glucosespiegel amputatie 202141-46 canagliflozine 202141-46 dapagliflozine 202141-46 diabetes mellitus type 2 202141-46 empagliflozine 202141-46 ertugliflozine 202141-46 gangreen van Fournier 202141-46 hartfalen 202141-46 hba1c 202141-46 keto-acidose 202141-46 metformine 202141-46 secundaire preventie 202141-46 sglt-2-remmers 202141-46 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46 hartfalen amputatie 202141-46 canagliflozine 202141-46 dapagliflozine 202141-46 diabetes mellitus type 2 202141-46 empagliflozine 202141-46 ertugliflozine 202141-46 gangreen van Fournier 202141-46 glucosespiegel 202141-46 hba1c 202141-46 keto-acidose 202141-46 metformine 202141-46 secundaire preventie 202141-46 sglt-2-remmers 202141-46 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46 hartritmestoornis aritmie 202117-20 atrium flutter 202117-20 atriumfibrilleren 202117-20 medisch hulpmiddel 202117-20 medische app 202117-20 screening 202117-20 hba1c amputatie 202141-46 canagliflozine 202141-46 dapagliflozine 202141-46 diabetes mellitus type 2 202141-46 empagliflozine 202141-46 ertugliflozine 202141-46 gangreen van Fournier 202141-46 glucosespiegel 202141-46 hartfalen 202141-46 keto-acidose 202141-46 metformine 202141-46 secundaire preventie 202141-46 sglt-2-remmers 202141-46 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46 hersenbloeding CVA 20211-4 LDL-cholesterol 20211-4 TIA 20211-4 angina 20211-4 beroerte 20211-4 cardiovasculair 20211-4 cerebrovasculair 20211-4 ezetimib 20211-4 herseninfarct 20211-4 myocardinfarct 20211-4 revascularisatie 20211-4 richtlijnen 20211-4 statinen 20211-4 streefwaarden 20211-4 herseninfarct CVA 20211-4 LDL-cholesterol 20211-4 TIA 20211-4 angina 20211-4 beroerte 20211-4 cardiovasculair 20211-4 cerebrovasculair 20211-4 ezetimib 20211-4 hersenbloeding 20211-4 myocardinfarct 20211-4 revascularisatie 20211-4 richtlijnen 20211-4 statinen 20211-4 streefwaarden 20211-4 HPV AIS 202147-56 CRPS 202147-56 Cervarix 202147-56 Gardasil 202147-56 POTS 202147-56 baarmoederhalskanker 202147-56 bivalent 202147-56 cervixcarcinoom 202147-56 humaan papillomavirus 202147-56 nonavalent 202147-56 quadrivalent 202147-56 vaccinatie 202147-56 vermoeidheidssyndroom 202147-56 humaan papillomavirus AIS 202147-56 CRPS 202147-56 Cervarix 202147-56 Gardasil 202147-56 HPV 202147-56 POTS 202147-56 baarmoederhalskanker 202147-56 bivalent 202147-56 cervixcarcinoom 202147-56 nonavalent 202147-56 quadrivalent 202147-56 vaccinatie 202147-56 vermoeidheidssyndroom 202147-56 imdevimab SARS-CoV-2 2021 bamlanivimab 2021 casirivimab 2021 covid-19 2021 covidpandemie 2021 covidpatiënten 2021 etesevimab 2021 immuungecompromitteerden 2021 longcovid 2021 monoklonale antilichamen 2021 neutraliserende monoklonale antilichamen 2021 pandemie 2021 regdanvimab 2021 sotrovimab 2021 immuungecompromitteerden SARS-CoV-2 2021 bamlanivimab 2021 casirivimab 2021 covid-19 2021 covidpandemie 2021 covidpatiënten 2021 etesevimab 2021 imdevimab 2021 longcovid 2021 monoklonale antilichamen 2021 neutraliserende monoklonale antilichamen 2021 pandemie 2021 regdanvimab 2021 sotrovimab 2021 in-stent-restenose MACE 2021 canakinumab 2021 cardiovasculaire mortaliteit 2021 colchicine 2021 coronaire hartziekten 2021 myocardinfarct 2021 secundaire preventie 2021 stents 2021 interleukine-6-antagonist COVID-19 202163-68 SARS-CoV-2 202163-68 corticosteroïden 202163-68 covidpneumonie 202163-68 dexamethason 202163-68 pandemie 202163-68 sarilumab 202163-68 tocilizumab 202163-68 zuurstoftherapie 202163-68 intermediate metabolizer CYP2C19 20219-12 P2Y12-remmers 20219-12 PCI 20219-12 clopidogrel 20219-12 cytochroom P450 20219-12 genotypering 20219-12 leverenzymen 20219-12 percutane coronaire interventie 20219-12 poor metabolizer 20219-12 prasugrel 20219-12 stentplaatsing 20219-12 stents 20219-12 ticagrelor 20219-12 tromboseprofylaxe 20219-12 Janssen Ad26.COV2-S-vaccin 202129-34 AstraZenica 202129-34 CanSino 202129-34 ChAdOx1-S-vaccin 202129-34 Sputnik 202129-34 Vaxzevria® 202129-34 Vectorvaccins 202129-34 covid 202129-34 covid-19 202129-34 pandemie 202129-34 vaccin 202129-34 keto-acidose amputatie 202141-46 canagliflozine 202141-46 dapagliflozine 202141-46 diabetes mellitus type 2 202141-46 empagliflozine 202141-46 ertugliflozine 202141-46 gangreen van Fournier 202141-46 glucosespiegel 202141-46 hartfalen 202141-46 hba1c 202141-46 metformine 202141-46 secundaire preventie 202141-46 sglt-2-remmers 202141-46 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46 LDL-cholesterol CVA 20211-4 TIA 20211-4 angina 20211-4 beroerte 20211-4 cardiovasculair 20211-4 cerebrovasculair 20211-4 ezetimib 20211-4 hersenbloeding 20211-4 herseninfarct 20211-4 myocardinfarct 20211-4 revascularisatie 20211-4 richtlijnen 20211-4 statinen 20211-4 streefwaarden 20211-4 leverenzymen CYP2C19 20219-12 P2Y12-remmers 20219-12 PCI 20219-12 clopidogrel 20219-12 cytochroom P450 20219-12 genotypering 20219-12 intermediate metabolizer 20219-12 percutane coronaire interventie 20219-12 poor metabolizer 20219-12 prasugrel 20219-12 stentplaatsing 20219-12 stents 20219-12 ticagrelor 20219-12 tromboseprofylaxe 20219-12 longcovid SARS-CoV-2 2021 bamlanivimab 2021 casirivimab 2021 covid-19 2021 covidpandemie 2021 covidpatiënten 2021 etesevimab 2021 imdevimab 2021 immuungecompromitteerden 2021 monoklonale antilichamen 2021 neutraliserende monoklonale antilichamen 2021 pandemie 2021 regdanvimab 2021 sotrovimab 2021 MACE canakinumab 2021 cardiovasculaire mortaliteit 2021 colchicine 2021 coronaire hartziekten 2021 in-stent-restenose 2021 myocardinfarct 2021 secundaire preventie 2021 stents 2021 medisch hulpmiddel aritmie 202117-20 atrium flutter 202117-20 atriumfibrilleren 202117-20 hartritmestoornis 202117-20 medische app 202117-20 screening 202117-20 medische app aritmie 202117-20 atrium flutter 202117-20 atriumfibrilleren 202117-20 hartritmestoornis 202117-20 medisch hulpmiddel 202117-20 screening 202117-20 messenger-RNA COVID-19 202113-16 Comirnaty 202113-16 Moderna 202113-16 SARS-CoV-2 202113-16 beschermingsduur 202113-16 doelgroep 202113-16 mRNA 202113-16 pandemie 202113-16 tozinameran 202113-16 uitwisselbaarheid 202113-16 vaccin 202113-16 virusmutatie 202113-16 meta-analyse Aktiprol® 202121-28 amisulpride 202121-28 antipsychotica 202121-28 bijwerkingen 202121-28 netwerk meta-analyse 202121-28 metformine amputatie 202141-46 canagliflozine 202141-46 dapagliflozine 202141-46 diabetes mellitus type 2 202141-46 empagliflozine 202141-46 ertugliflozine 202141-46 gangreen van Fournier 202141-46 glucosespiegel 202141-46 hartfalen 202141-46 hba1c 202141-46 keto-acidose 202141-46 secundaire preventie 202141-46 sglt-2-remmers 202141-46 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46 Moderna COVID-19 202113-16 Comirnaty 202113-16 SARS-CoV-2 202113-16 beschermingsduur 202113-16 doelgroep 202113-16 mRNA 202113-16 messenger-RNA 202113-16 pandemie 202113-16 tozinameran 202113-16 uitwisselbaarheid 202113-16 vaccin 202113-16 virusmutatie 202113-16 monoklonale antilichamen SARS-CoV-2 2021 bamlanivimab 2021 casirivimab 2021 covid-19 2021 covidpandemie 2021 covidpatiënten 2021 etesevimab 2021 imdevimab 2021 immuungecompromitteerden 2021 longcovid 2021 neutraliserende monoklonale antilichamen 2021 pandemie 2021 regdanvimab 2021 sotrovimab 2021 mRNA COVID-19 202113-16 Comirnaty 202113-16 Moderna 202113-16 SARS-CoV-2 202113-16 beschermingsduur 202113-16 doelgroep 202113-16 messenger-RNA 202113-16 pandemie 202113-16 tozinameran 202113-16 uitwisselbaarheid 202113-16 vaccin 202113-16 virusmutatie 202113-16 myocardinfarct CVA 20211-4 EMA 202157-62 FDA 202157-62 LDL-cholesterol 20211-4 MACE 2021 TIA 20211-4 angina 20211-4 beroerte 20211-4 bijwerkingen 202157-62 bloedglucoseverlagende middel 202157-62 canakinumab 2021 cardiovasculair 20211-4 cardiovasculaire mortaliteit 2021 cerebrovasculair 20211-4 colchicine 2021 coronaire hartziekten 2021 diabetes 202157-62 ezetimib 20211-4 gerandomiseerd onderzoek 202157-62 hersenbloeding 20211-4 herseninfarct 20211-4 in-stent-restenose 2021 observationeel onderzoek 202157-62 registratie 202157-62 revascularisatie 20211-4 richtlijnen 20211-4 richtlijnen 202157-62 rosiglitazon 202157-62 secundaire preventie 2021 statinen 20211-4 stents 2021 streefwaarden 20211-4 netwerk meta-analyse Aktiprol® 202121-28 amisulpride 202121-28 antipsychotica 202121-28 bijwerkingen 202121-28 meta-analyse 202121-28 neutraliserende monoklonale antilichamen SARS-CoV-2 2021 bamlanivimab 2021 casirivimab 2021 covid-19 2021 covidpandemie 2021 covidpatiënten 2021 etesevimab 2021 imdevimab 2021 immuungecompromitteerden 2021 longcovid 2021 monoklonale antilichamen 2021 pandemie 2021 regdanvimab 2021 sotrovimab 2021 niet-kleincellig longcarcinoom EGFR-tyrokinaseremmer 202135-40 Erlotinib 202135-40 NSCLC 202135-40 Tarceva® 202135-40 epidermale groeifactorreceptor 202135-40 extramurale behandeling 202135-40 overleving 202135-40 progressievrij 202135-40 nonavalent AIS 202147-56 CRPS 202147-56 Cervarix 202147-56 Gardasil 202147-56 HPV 202147-56 POTS 202147-56 baarmoederhalskanker 202147-56 bivalent 202147-56 cervixcarcinoom 202147-56 humaan papillomavirus 202147-56 quadrivalent 202147-56 vaccinatie 202147-56 vermoeidheidssyndroom 202147-56 NSCLC EGFR-tyrokinaseremmer 202135-40 Erlotinib 202135-40 Tarceva® 202135-40 epidermale groeifactorreceptor 202135-40 extramurale behandeling 202135-40 niet-kleincellig longcarcinoom 202135-40 overleving 202135-40 progressievrij 202135-40 observationeel onderzoek EMA 202157-62 FDA 202157-62 bijwerkingen 202157-62 bloedglucoseverlagende middel 202157-62 diabetes 202157-62 gerandomiseerd onderzoek 202157-62 myocardinfarct 202157-62 registratie 202157-62 richtlijnen 202157-62 rosiglitazon 202157-62 overleving EGFR-tyrokinaseremmer 202135-40 Erlotinib 202135-40 NSCLC 202135-40 Tarceva® 202135-40 epidermale groeifactorreceptor 202135-40 extramurale behandeling 202135-40 niet-kleincellig longcarcinoom 202135-40 progressievrij 202135-40 P2Y12-remmers CYP2C19 20219-12 PCI 20219-12 clopidogrel 20219-12 cytochroom P450 20219-12 genotypering 20219-12 intermediate metabolizer 20219-12 leverenzymen 20219-12 percutane coronaire interventie 20219-12 poor metabolizer 20219-12 prasugrel 20219-12 stentplaatsing 20219-12 stents 20219-12 ticagrelor 20219-12 tromboseprofylaxe 20219-12 pandemie Ad26.COV2-S-vaccin 202129-34 AstraZenica 202129-34 COVID-19 202113-16 COVID-19 202163-68 CanSino 202129-34 ChAdOx1-S-vaccin 202129-34 Comirnaty 202113-16 Janssen 202129-34 Moderna 202113-16 SARS-CoV-2 202113-16 SARS-CoV-2 202163-68 SARS-CoV-2 2021 Sputnik 202129-34 Vaxzevria® 202129-34 Vectorvaccins 202129-34 bamlanivimab 2021 beschermingsduur 202113-16 casirivimab 2021 corticosteroïden 202163-68 covid 202129-34 covid-19 202129-34 covid-19 2021 covidpandemie 2021 covidpatiënten 2021 covidpneumonie 202163-68 dexamethason 202163-68 doelgroep 202113-16 etesevimab 2021 imdevimab 2021 immuungecompromitteerden 2021 interleukine-6-antagonist 202163-68 longcovid 2021 mRNA 202113-16 messenger-RNA 202113-16 monoklonale antilichamen 2021 neutraliserende monoklonale antilichamen 2021 regdanvimab 2021 sarilumab 202163-68 sotrovimab 2021 tocilizumab 202163-68 tozinameran 202113-16 uitwisselbaarheid 202113-16 vaccin 202113-16 vaccin 202129-34 virusmutatie 202113-16 zuurstoftherapie 202163-68 PCI CYP2C19 20219-12 P2Y12-remmers 20219-12 clopidogrel 20219-12 cytochroom P450 20219-12 genotypering 20219-12 intermediate metabolizer 20219-12 leverenzymen 20219-12 percutane coronaire interventie 20219-12 poor metabolizer 20219-12 prasugrel 20219-12 stentplaatsing 20219-12 stents 20219-12 ticagrelor 20219-12 tromboseprofylaxe 20219-12 percutane coronaire interventie CYP2C19 20219-12 P2Y12-remmers 20219-12 PCI 20219-12 clopidogrel 20219-12 cytochroom P450 20219-12 genotypering 20219-12 intermediate metabolizer 20219-12 leverenzymen 20219-12 poor metabolizer 20219-12 prasugrel 20219-12 stentplaatsing 20219-12 stents 20219-12 ticagrelor 20219-12 tromboseprofylaxe 20219-12 poor metabolizer CYP2C19 20219-12 P2Y12-remmers 20219-12 PCI 20219-12 clopidogrel 20219-12 cytochroom P450 20219-12 genotypering 20219-12 intermediate metabolizer 20219-12 leverenzymen 20219-12 percutane coronaire interventie 20219-12 prasugrel 20219-12 stentplaatsing 20219-12 stents 20219-12 ticagrelor 20219-12 tromboseprofylaxe 20219-12 post-marketing surveillance bijwerkingen 20215-7 epidemiologisch onderzoek 20215-7 registratieonderzoek 20215-7 vaccins 20215-7 vaccinvigilantie 20215-7 POTS AIS 202147-56 CRPS 202147-56 Cervarix 202147-56 Gardasil 202147-56 HPV 202147-56 baarmoederhalskanker 202147-56 bivalent 202147-56 cervixcarcinoom 202147-56 humaan papillomavirus 202147-56 nonavalent 202147-56 quadrivalent 202147-56 vaccinatie 202147-56 vermoeidheidssyndroom 202147-56 prasugrel CYP2C19 20219-12 P2Y12-remmers 20219-12 PCI 20219-12 clopidogrel 20219-12 cytochroom P450 20219-12 genotypering 20219-12 intermediate metabolizer 20219-12 leverenzymen 20219-12 percutane coronaire interventie 20219-12 poor metabolizer 20219-12 stentplaatsing 20219-12 stents 20219-12 ticagrelor 20219-12 tromboseprofylaxe 20219-12 progressievrij EGFR-tyrokinaseremmer 202135-40 Erlotinib 202135-40 NSCLC 202135-40 Tarceva® 202135-40 epidermale groeifactorreceptor 202135-40 extramurale behandeling 202135-40 niet-kleincellig longcarcinoom 202135-40 overleving 202135-40 quadrivalent AIS 202147-56 CRPS 202147-56 Cervarix 202147-56 Gardasil 202147-56 HPV 202147-56 POTS 202147-56 baarmoederhalskanker 202147-56 bivalent 202147-56 cervixcarcinoom 202147-56 humaan papillomavirus 202147-56 nonavalent 202147-56 vaccinatie 202147-56 vermoeidheidssyndroom 202147-56 regdanvimab SARS-CoV-2 2021 bamlanivimab 2021 casirivimab 2021 covid-19 2021 covidpandemie 2021 covidpatiënten 2021 etesevimab 2021 imdevimab 2021 immuungecompromitteerden 2021 longcovid 2021 monoklonale antilichamen 2021 neutraliserende monoklonale antilichamen 2021 pandemie 2021 sotrovimab 2021 registratie EMA 202157-62 FDA 202157-62 bijwerkingen 202157-62 bloedglucoseverlagende middel 202157-62 diabetes 202157-62 gerandomiseerd onderzoek 202157-62 myocardinfarct 202157-62 observationeel onderzoek 202157-62 richtlijnen 202157-62 rosiglitazon 202157-62 registratieonderzoek bijwerkingen 20215-7 epidemiologisch onderzoek 20215-7 post-marketing surveillance 20215-7 vaccins 20215-7 vaccinvigilantie 20215-7 revascularisatie CVA 20211-4 LDL-cholesterol 20211-4 TIA 20211-4 angina 20211-4 beroerte 20211-4 cardiovasculair 20211-4 cerebrovasculair 20211-4 ezetimib 20211-4 hersenbloeding 20211-4 herseninfarct 20211-4 myocardinfarct 20211-4 richtlijnen 20211-4 statinen 20211-4 streefwaarden 20211-4 richtlijnen CVA 20211-4 EMA 202157-62 FDA 202157-62 LDL-cholesterol 20211-4 TIA 20211-4 angina 20211-4 beroerte 20211-4 bijwerkingen 202157-62 bloedglucoseverlagende middel 202157-62 cardiovasculair 20211-4 cerebrovasculair 20211-4 diabetes 202157-62 ezetimib 20211-4 gerandomiseerd onderzoek 202157-62 hersenbloeding 20211-4 herseninfarct 20211-4 myocardinfarct 20211-4 myocardinfarct 202157-62 observationeel onderzoek 202157-62 registratie 202157-62 revascularisatie 20211-4 rosiglitazon 202157-62 statinen 20211-4 streefwaarden 20211-4 rosiglitazon EMA 202157-62 FDA 202157-62 bijwerkingen 202157-62 bloedglucoseverlagende middel 202157-62 diabetes 202157-62 gerandomiseerd onderzoek 202157-62 myocardinfarct 202157-62 observationeel onderzoek 202157-62 registratie 202157-62 richtlijnen 202157-62 sarilumab COVID-19 202163-68 SARS-CoV-2 202163-68 corticosteroïden 202163-68 covidpneumonie 202163-68 dexamethason 202163-68 interleukine-6-antagonist 202163-68 pandemie 202163-68 tocilizumab 202163-68 zuurstoftherapie 202163-68 SARS-CoV-2 COVID-19 202113-16 COVID-19 202163-68 Comirnaty 202113-16 Moderna 202113-16 bamlanivimab 2021 beschermingsduur 202113-16 casirivimab 2021 corticosteroïden 202163-68 covid-19 2021 covidpandemie 2021 covidpatiënten 2021 covidpneumonie 202163-68 dexamethason 202163-68 doelgroep 202113-16 etesevimab 2021 imdevimab 2021 immuungecompromitteerden 2021 interleukine-6-antagonist 202163-68 longcovid 2021 mRNA 202113-16 messenger-RNA 202113-16 monoklonale antilichamen 2021 neutraliserende monoklonale antilichamen 2021 pandemie 202113-16 pandemie 202163-68 pandemie 2021 regdanvimab 2021 sarilumab 202163-68 sotrovimab 2021 tocilizumab 202163-68 tozinameran 202113-16 uitwisselbaarheid 202113-16 vaccin 202113-16 virusmutatie 202113-16 zuurstoftherapie 202163-68 screening aritmie 202117-20 atrium flutter 202117-20 atriumfibrilleren 202117-20 hartritmestoornis 202117-20 medisch hulpmiddel 202117-20 medische app 202117-20 secundaire preventie MACE 2021 amputatie 202141-46 canagliflozine 202141-46 canakinumab 2021 cardiovasculaire mortaliteit 2021 colchicine 2021 coronaire hartziekten 2021 dapagliflozine 202141-46 diabetes mellitus type 2 202141-46 empagliflozine 202141-46 ertugliflozine 202141-46 gangreen van Fournier 202141-46 glucosespiegel 202141-46 hartfalen 202141-46 hba1c 202141-46 in-stent-restenose 2021 keto-acidose 202141-46 metformine 202141-46 myocardinfarct 2021 sglt-2-remmers 202141-46 stents 2021 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46 sglt-2-remmers amputatie 202141-46 canagliflozine 202141-46 dapagliflozine 202141-46 diabetes mellitus type 2 202141-46 empagliflozine 202141-46 ertugliflozine 202141-46 gangreen van Fournier 202141-46 glucosespiegel 202141-46 hartfalen 202141-46 hba1c 202141-46 keto-acidose 202141-46 metformine 202141-46 secundaire preventie 202141-46 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46 sotrovimab SARS-CoV-2 2021 bamlanivimab 2021 casirivimab 2021 covid-19 2021 covidpandemie 2021 covidpatiënten 2021 etesevimab 2021 imdevimab 2021 immuungecompromitteerden 2021 longcovid 2021 monoklonale antilichamen 2021 neutraliserende monoklonale antilichamen 2021 pandemie 2021 regdanvimab 2021 Sputnik Ad26.COV2-S-vaccin 202129-34 AstraZenica 202129-34 CanSino 202129-34 ChAdOx1-S-vaccin 202129-34 Janssen 202129-34 Vaxzevria® 202129-34 Vectorvaccins 202129-34 covid 202129-34 covid-19 202129-34 pandemie 202129-34 vaccin 202129-34 statinen CVA 20211-4 LDL-cholesterol 20211-4 TIA 20211-4 angina 20211-4 beroerte 20211-4 cardiovasculair 20211-4 cerebrovasculair 20211-4 ezetimib 20211-4 hersenbloeding 20211-4 herseninfarct 20211-4 myocardinfarct 20211-4 revascularisatie 20211-4 richtlijnen 20211-4 streefwaarden 20211-4 stentplaatsing CYP2C19 20219-12 P2Y12-remmers 20219-12 PCI 20219-12 clopidogrel 20219-12 cytochroom P450 20219-12 genotypering 20219-12 intermediate metabolizer 20219-12 leverenzymen 20219-12 percutane coronaire interventie 20219-12 poor metabolizer 20219-12 prasugrel 20219-12 stents 20219-12 ticagrelor 20219-12 tromboseprofylaxe 20219-12 stents CYP2C19 20219-12 MACE 2021 P2Y12-remmers 20219-12 PCI 20219-12 canakinumab 2021 cardiovasculaire mortaliteit 2021 clopidogrel 20219-12 colchicine 2021 coronaire hartziekten 2021 cytochroom P450 20219-12 genotypering 20219-12 in-stent-restenose 2021 intermediate metabolizer 20219-12 leverenzymen 20219-12 myocardinfarct 2021 percutane coronaire interventie 20219-12 poor metabolizer 20219-12 prasugrel 20219-12 secundaire preventie 2021 stentplaatsing 20219-12 ticagrelor 20219-12 tromboseprofylaxe 20219-12 streefwaarden CVA 20211-4 LDL-cholesterol 20211-4 TIA 20211-4 angina 20211-4 beroerte 20211-4 cardiovasculair 20211-4 cerebrovasculair 20211-4 ezetimib 20211-4 hersenbloeding 20211-4 herseninfarct 20211-4 myocardinfarct 20211-4 revascularisatie 20211-4 richtlijnen 20211-4 statinen 20211-4 sulfonylureumderivaten amputatie 202141-46 canagliflozine 202141-46 dapagliflozine 202141-46 diabetes mellitus type 2 202141-46 empagliflozine 202141-46 ertugliflozine 202141-46 gangreen van Fournier 202141-46 glucosespiegel 202141-46 hartfalen 202141-46 hba1c 202141-46 keto-acidose 202141-46 metformine 202141-46 secundaire preventie 202141-46 sglt-2-remmers 202141-46 urineweginfecties 202141-46 Tarceva® EGFR-tyrokinaseremmer 202135-40 Erlotinib 202135-40 NSCLC 202135-40 epidermale groeifactorreceptor 202135-40 extramurale behandeling 202135-40 niet-kleincellig longcarcinoom 202135-40 overleving 202135-40 progressievrij 202135-40 TIA CVA 20211-4 LDL-cholesterol 20211-4 angina 20211-4 beroerte 20211-4 cardiovasculair 20211-4 cerebrovasculair 20211-4 ezetimib 20211-4 hersenbloeding 20211-4 herseninfarct 20211-4 myocardinfarct 20211-4 revascularisatie 20211-4 richtlijnen 20211-4 statinen 20211-4 streefwaarden 20211-4 ticagrelor CYP2C19 20219-12 P2Y12-remmers 20219-12 PCI 20219-12 clopidogrel 20219-12 cytochroom P450 20219-12 genotypering 20219-12 intermediate metabolizer 20219-12 leverenzymen 20219-12 percutane coronaire interventie 20219-12 poor metabolizer 20219-12 prasugrel 20219-12 stentplaatsing 20219-12 stents 20219-12 tromboseprofylaxe 20219-12 tocilizumab COVID-19 202163-68 SARS-CoV-2 202163-68 corticosteroïden 202163-68 covidpneumonie 202163-68 dexamethason 202163-68 interleukine-6-antagonist 202163-68 pandemie 202163-68 sarilumab 202163-68 zuurstoftherapie 202163-68 tozinameran COVID-19 202113-16 Comirnaty 202113-16 Moderna 202113-16 SARS-CoV-2 202113-16 beschermingsduur 202113-16 doelgroep 202113-16 mRNA 202113-16 messenger-RNA 202113-16 pandemie 202113-16 uitwisselbaarheid 202113-16 vaccin 202113-16 virusmutatie 202113-16 tromboseprofylaxe CYP2C19 20219-12 P2Y12-remmers 20219-12 PCI 20219-12 clopidogrel 20219-12 cytochroom P450 20219-12 genotypering 20219-12 intermediate metabolizer 20219-12 leverenzymen 20219-12 percutane coronaire interventie 20219-12 poor metabolizer 20219-12 prasugrel 20219-12 stentplaatsing 20219-12 stents 20219-12 ticagrelor 20219-12 uitwisselbaarheid COVID-19 202113-16 Comirnaty 202113-16 Moderna 202113-16 SARS-CoV-2 202113-16 beschermingsduur 202113-16 doelgroep 202113-16 mRNA 202113-16 messenger-RNA 202113-16 pandemie 202113-16 tozinameran 202113-16 vaccin 202113-16 virusmutatie 202113-16 urineweginfecties amputatie 202141-46 canagliflozine 202141-46 dapagliflozine 202141-46 diabetes mellitus type 2 202141-46 empagliflozine 202141-46 ertugliflozine 202141-46 gangreen van Fournier 202141-46 glucosespiegel 202141-46 hartfalen 202141-46 hba1c 202141-46 keto-acidose 202141-46 metformine 202141-46 secundaire preventie 202141-46 sglt-2-remmers 202141-46 sulfonylureumderivaten 202141-46 vaccin Ad26.COV2-S-vaccin 202129-34 AstraZenica 202129-34 COVID-19 202113-16 CanSino 202129-34 ChAdOx1-S-vaccin 202129-34 Comirnaty 202113-16 Janssen 202129-34 Moderna 202113-16 SARS-CoV-2 202113-16 Sputnik 202129-34 Vaxzevria® 202129-34 Vectorvaccins 202129-34 beschermingsduur 202113-16 covid 202129-34 covid-19 202129-34 doelgroep 202113-16 mRNA 202113-16 messenger-RNA 202113-16 pandemie 202113-16 pandemie 202129-34 tozinameran 202113-16 uitwisselbaarheid 202113-16 virusmutatie 202113-16 vaccinatie AIS 202147-56 CRPS 202147-56 Cervarix 202147-56 Gardasil 202147-56 HPV 202147-56 POTS 202147-56 baarmoederhalskanker 202147-56 bivalent 202147-56 cervixcarcinoom 202147-56 humaan papillomavirus 202147-56 nonavalent 202147-56 quadrivalent 202147-56 vermoeidheidssyndroom 202147-56 vaccins bijwerkingen 20215-7 epidemiologisch onderzoek 20215-7 post-marketing surveillance 20215-7 registratieonderzoek 20215-7 vaccinvigilantie 20215-7 vaccinvigilantie bijwerkingen 20215-7 epidemiologisch onderzoek 20215-7 post-marketing surveillance 20215-7 registratieonderzoek 20215-7 vaccins 20215-7 Vaxzevria® Ad26.COV2-S-vaccin 202129-34 AstraZenica 202129-34 CanSino 202129-34 ChAdOx1-S-vaccin 202129-34 Janssen 202129-34 Sputnik 202129-34 Vectorvaccins 202129-34 covid 202129-34 covid-19 202129-34 pandemie 202129-34 vaccin 202129-34 Vectorvaccins Ad26.COV2-S-vaccin 202129-34 AstraZenica 202129-34 CanSino 202129-34 ChAdOx1-S-vaccin 202129-34 Janssen 202129-34 Sputnik 202129-34 Vaxzevria® 202129-34 covid 202129-34 covid-19 202129-34 pandemie 202129-34 vaccin 202129-34 vermoeidheidssyndroom AIS 202147-56 CRPS 202147-56 Cervarix 202147-56 Gardasil 202147-56 HPV 202147-56 POTS 202147-56 baarmoederhalskanker 202147-56 bivalent 202147-56 cervixcarcinoom 202147-56 humaan papillomavirus 202147-56 nonavalent 202147-56 quadrivalent 202147-56 vaccinatie 202147-56 virusmutatie COVID-19 202113-16 Comirnaty 202113-16 Moderna 202113-16 SARS-CoV-2 202113-16 beschermingsduur 202113-16 doelgroep 202113-16 mRNA 202113-16 messenger-RNA 202113-16 pandemie 202113-16 tozinameran 202113-16 uitwisselbaarheid 202113-16 vaccin 202113-16 zuurstoftherapie COVID-19 202163-68 SARS-CoV-2 202163-68 corticosteroïden 202163-68 covidpneumonie 202163-68 dexamethason 202163-68 interleukine-6-antagonist 202163-68 pandemie 202163-68 sarilumab 202163-68 tocilizumab 202163-68